Quest Diagnostics Inc
DGX- Exchange
- NYSE
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001022079
In the last 90 days, Quest Diagnostics Inc insiders filed 0 open-market purchases and 3 sales; 1,112 institutions reported holding it in 13F filings for Q2 2026, worth $22.2B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Quest Diagnostics Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 3 insiders, $8.32M in total
- Insiders trading
- 3
- Net value
- −$8.32M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Quest Diagnostics Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Davis J. E. | CEO and President | 122,423 | Sep 3, 2026 | 7 |
| Prevoznik Michael E | SVP & General Counsel | 36,557 | Aug 31, 2026 | 5 |
| Delaney Mark E | SVP & Chief Commercial Officer | 10,335 | Jul 29, 2026 | 8 |
| Kuppusamy Karthik | SVP, Clinical Solutions | 13,557 | Jul 27, 2026 | 7 |
| Carter Robert B | Director | 3,864 | Jul 27, 2026 | 5 |
| Gregg Vicky B | Director | 18,386 | Jul 27, 2026 | 6 |
| Plewman Patrick | SVP for Diagnostic Services | 15,293 | Jul 27, 2026 | 7 |
| Main Timothy L | Director | 22,460 | Jul 27, 2026 | 2 |
| Samad Sam | Executive Vice President & CFO | 33,478 | Jul 27, 2026 | 6 |
| Lassiter Wright III | Director | 10,323 | Jul 27, 2026 | 5 |
| Wentworth Timothy C | Director | 1,358 | Jul 2, 2026 | 4 |
| Pfeiffer Gary M | Director | 31,005 | May 21, 2026 | 2 |
| Ring Timothy M | Director | 31,140 | May 21, 2026 | 2 |
| Morrison Denise M | Director | 11,929 | May 21, 2026 | 1 |
| Doi Tracey | Director | 7,748 | May 21, 2026 | 1 |
| Diaz Luis | Director | 5,196 | May 21, 2026 | 1 |
| Doherty Catherine T. | EVP, Regional Businesses | 67,122 | Mar 6, 2026 | 4 |
| Deppe Michael J | SVP, Corp. Controller & CAO | 35,196 | Mar 6, 2026 | 3 |
| Gardner Mark A | SVP of Molecular Gen & Oncol | 4,673 | Sep 26, 2024 | 0 |
| Wilensky Gail R | Director | 20,506 | May 19, 2023 | 0 |
| Rusckowski Stephen H | Director | 389,597 | Mar 8, 2023 | 0 |
| Guinan Mark | Executive Vice President & CFO | 98,981 | Mar 9, 2022 | 0 |
| Eglinton Manner Carrie | SVP, Advanced Diagnostics | 48,391 | Mar 9, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2024 (view filing) | Apr 29 | 2 days | Kuppusamy KarthikSVP, Clinical Solutions | SSale | −1.76K | $140.00 | −$246.4K | −11.6%13.4K after | 10b5-1 |
| Mar 1, 2024 (view filing) | Feb 28-29 | 2 days | Doherty Catherine T.EVP, Regional Businesses | SSale | −6.74K | $126.45 | −$852.8K | −9.0%68.4K after | 2 lots10b5-1 |
| Mar 1, 2024 (view filing) | Feb 29 | 1 day | Prevoznik Michael ESVP & General Counsel | SSale | −5.61K | $125.88 | −$706.3K | −12.7%38.5K after | 10b5-1 |
| Feb 23, 2024 (view filing) | Feb 22 | 1 day | Prevoznik Michael ESVP & General Counsel | SSale | −661 | $126.14 | −$83.4K | −1.6%40.2K after | 10b5-1 |
| Feb 23, 2024 (view filing) | Feb 23 | Same day | Gregg Vicky BDirector | SSale | −2.50K | $126.64 | −$316.6K | −13.3%16.3K after | |
| Feb 23, 2024 (view filing) | Feb 22 | 1 day | Doherty Catherine T.EVP, Regional Businesses | SSale | −821 | $126.14 | −$103.6K | −1.1%70.8K after | 10b5-1 |
| Mar 8, 2023 (view filing) | Mar 7 | 1 day | Prevoznik Michael ESVP & General Counsel | SSale | −4.75K | $140.55 | −$668.2K | −11.0%38.5K after | |
| Mar 8, 2023 (view filing) | Mar 7 | 1 day | Doherty Catherine T.SVP, Regional Businesses | SSale | −5.31K | $140.55 | −$745.9K | −7.3%67.8K after | |
| Mar 6, 2023 (view filing) | Mar 3 | 3 days | Doherty Catherine T.SVP, Regional Businesses | SSale | −717 | $140.63 | −$100.8K | −1.0%67.8K after | |
| Mar 3, 2023 (view filing) | Mar 2 | 1 day | Prevoznik Michael ESVP & General Counsel | SSale | −593 | $138.54 | −$82.2K | −1.5%38.5K after | |
| Feb 27, 2023 (view filing) | Feb 24 | 3 days | Prevoznik Michael ESVP & General Counsel | SSale | −1.42K | $141.42 | −$200.1K | −3.5%39.4K after | |
| Feb 27, 2023 (view filing) | Feb 24 | 3 days | Doherty Catherine T.SVP, Regional Businesses | SSale | −1.69K | $141.42 | −$239.0K | −2.4%68.9K after | |
| Dec 5, 2022 (view filing) | Dec 1 | 4 days | Ring Timothy MDirector | SSale | −2.02K | $152.50 | −$308.8K | −7.7%24.1K after | |
| Nov 29, 2022 (view filing) | Nov 28 | 1 day | Doherty Catherine T.SVP, Regional Businesses | SSale | −40.8K | $149.18 | −$6.08M | −37.6%67.7K after | 2 lots |
| Nov 2, 2022 (view filing) | Nov 1 | 1 day | Ring Timothy MDirector | SSale | −2.00K | $144.06 | −$288.1K | −7.6%24.1K after | |
| Oct 27, 2022 (view filing) | Oct 26 | 1 day | Deppe Michael JVP, Corp. Controller & CAO | SSale | −15.5K | $145.00 | −$2.25M | −32.6%32.0K after | |
| Oct 4, 2022 (view filing) | Oct 3 | 1 day | Ring Timothy MDirector | SSale | −2.00K | $123.39 | −$246.8K | −7.7%23.9K after | |
| Sep 6, 2022 (view filing) | Sep 1 | 5 days | Ring Timothy MDirector | SSale | −2.00K | $125.02 | −$250.0K | −7.7%23.9K after | |
| Aug 2, 2022 (view filing) | Aug 1 | 1 day | Ring Timothy MDirector | SSale | −2.00K | $136.04 | −$272.1K | −7.7%23.9K after | |
| Jul 5, 2022 (view filing) | Jul 1 | 4 days | Ring Timothy MDirector | SSale | −2.00K | $133.47 | −$266.9K | −7.7%23.9K after | |
| May 26, 2022 (view filing) | May 25 | 1 day | Rusckowski Stephen HChairman, CEO and President | SSale | −24.9K | $140.89 | −$3.51M | −6.9%334.8K after | 6 lots |
| May 25, 2022 (view filing) | May 23-24 | 2 days | Rusckowski Stephen HChairman, CEO and President | SSale | −359.9K | $140.13 | −$50.4M | −51.8%334.8K after | 8 lots |
| May 19, 2022 (view filing) | May 17 | 2 days | Prevoznik Michael ESVP & General Counsel | SSale | −50.6K | $139.97 | −$7.08M | −56.3%39.2K after | |
| Mar 9, 2022 (view filing) | Mar 8 | 1 day | Prevoznik Michael ESVP & General Counsel | SSale | −6.23K | $135.21 | −$842.1K | −13.7%39.2K after | |
| Mar 9, 2022 (view filing) | Mar 8 | 1 day | Doherty Catherine T.SVP, Group Exec. Clin. Fran. | SSale | −7.03K | $135.21 | −$950.8K | −9.4%67.7K after | |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Prevoznik Michael ESVP & General Counsel | SSale | −661 | $130.00 | −$85.9K | −1.7%39.2K after | |
| Feb 28, 2022 (view filing) | Feb 24 | 4 days | Doherty Catherine T.SVP, Group Exec. Clin. Fran. | SSale | −2.75K | $126.26 | −$347.2K | −4.1%64.4K after | |
| Feb 28, 2022 (view filing) | Feb 24 | 4 days | Prevoznik Michael ESVP & General Counsel | SSale | −1.67K | $126.26 | −$210.7K | −4.3%37.1K after | |
| Dec 1, 2021 (view filing) | Nov 29 | 2 days | Doherty Catherine T.SVP, Group Exec. Clin. Fran. | SSale | −37.6K | $156.81 | −$5.89M | −35.3%68.7K after | 5 lots |
| Jul 30, 2021 (view filing) | Jul 28-29 | 2 days | Rusckowski Stephen HChairman, CEO and President | SSale | −149.2K | $140.19 | −$20.9M | −34.4%284.4K after | 3 lots |
| Jul 28, 2021 (view filing) | Jul 26-27 | 2 days | Rusckowski Stephen HChairman, CEO and President | SSale | −38.6K | $140.01 | −$5.40M | −11.9%284.4K after | 2 lots |
| Jul 28, 2021 (view filing) | Jul 27 | 1 day | Wilensky Gail RDirector | SSale | −12.2K | $139.30 | −$1.70M | −40.6%17.8K after | 2 lots |